BIOVIE INC (BIVI)
US09074F2074 - Common Stock
BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID
Authorization expands use of bezisterim in a Phase 2, placebo-controlled, multicenter trial assessing bezisterim’s impact on neurological symptoms...
Which stocks are moving before the opening bell on Wednesday?
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.
BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting
Bezisterim appears to possess broad homeostatic properties relevant to inflammation and human disorders related to aging Patients treated with bezisterim...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today!
BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson’s Disease
SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson’s disease who are naïve to...
BioVie Inc. Announces Reverse Stock Split
Shares of BioVie common stock began trading on split-adjusted basis on August 6, 2024...
BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress
Additional presentation will further characterize the potential impact of bezisterim on motor and specific non-motor symptoms of Parkinson’s disease...
Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on June 26
CARSON CITY, Nev., June 12, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing...
BIVI Stock Earnings: BioVie Beats EPS for Q3 2024
BIVI stock results show that BioVie beat analyst estimates for earnings per share the third quarter of 2024.
BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID
Increasing evidence supports a role for viral persistence, chronic inflammation and immune and metabolic dysregulation in driving long COVID Bezisterim,...
BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation
Additionally, the Company announced approval of the non-proprietary name “bezisterim” for NE3107...
Lawsuit Notice: Investors who lost money with BioVie Inc. (NASDAQ: BIVI) shares should contact the Shareholders Foundation
/PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit is pending for certain investors in BioVie Inc. (NASDAQ: BIVI) shares. Investors,...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioVie Inc. of Class Action Lawsuit and Upcoming Deadlines - BIVI
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against BioVie Inc. ("BioVie" or the "Company") (NASDAQ: BIVI) and certain...
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVie
BIVI DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages BioVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BIVI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
BIVI DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages BioVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BIVI
WHY: NEW YORK, NY - (NewMediaWire) - March 18, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioVie Inc. (NASDAQ: BIVI) between August 5, 2021 and November 29, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline.
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioVie Inc. (BIVI)
BIVI DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages BioVie Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - BIVI
WHY: NEW YORK, NY - (NewMediaWire) - March 17, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioVie Inc. (NASDAQ: BIVI) between August 5, 2021 and November 29, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline.
BIVI DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages BioVie Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - BIVI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
BIVI DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages BioVie Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - BIVI
WHY: NEW YORK, NY - (NewMediaWire) - March 16, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioVie Inc. (NASDAQ: BIVI) between August 5, 2021 and November 29, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline.
BIVI DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages BioVie Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - BIVI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
BIVI DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages BioVie Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 19 Deadline in Securities Class Action - BIVI
WHY: NEW YORK, NY - (NewMediaWire) - March 15, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioVie Inc. (NASDAQ: BIVI) between August 5, 2021 and November 29, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline.
BIVI DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages BioVie Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 19 Deadline in Securities Class Action - BIVI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Shareholders that lost money on BioVie Inc.(BIVI) should contact Levi & Korsinsky about pending Class Action - BIVI
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in BioVie Inc. ("BioVie" or the "Company") (NASDAQ: BIVI) of a class action securities lawsuit. CLASS...
BIVI DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioVie Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - BIVI
WHY: NEW YORK, NY - (NewMediaWire) - March 14, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioVie Inc. (NASDAQ: BIVI) between August 5, 2021 and November 29, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline.
BIVI DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioVie Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - BIVI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Holzer & Holzer, LLC Reminds Shareholders of the March 19, 2024 Lead Plaintiff Deadline in the BioVie Inc. (BIVI) Class Action - Nationally Ranked Investors' Rights Firm Encourages Investors With Significant Losses to Contact the Firm
ATLANTA, GA - (NewMediaWire) - March 14, 2024 - Holzer & Holzer, LLC reminds shareholders that the class action filed against BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI) has an upcoming March 19, 2024 Lead Plaintiff deadline.
Holzer & Holzer, LLC Reminds Shareholders of the March 19, 2024 Lead Plaintiff Deadline in the BioVie Inc. (BIVI) Class Action - Nationally Ranked Investors' Rights Firm Encourages Investors With Significant Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVie
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVie
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioVie Inc. ("BioVie" or the "Company")...